Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Alterations of Gut Microbiome Accelerate Multiple Myeloma Progression By Increasing the Relative Abundances of Nitrogen Recycling Bacteria

Xingxing Jian, PhD, Yinghong Zhu, Jian Ouyang, Qian Lei, Jiliang Xia, PhD, Jingyu Zhang, Jiaojiao Guo, Jinuo Wang, MD, Jingchao Lin, Mingming Su, Yongjun Guan, Guancheng Li, PhD, Minghua Wu, PhD, Jian Li, MD, Juanjuan Xiang, PhD, Lu Xie, PhD, Lugui Qiu, MD PhD, Wei Jia, PhD, Wen Zhou, PhD

Blood (2019) 134 (Supplement_1): 688.

https://doi.org/10.1182/blood-2019-125051

Published: 2019

Journal Articles

High Glycine Promotes Proliferation and Progression Though Increase of Glutathione Synthesis in Multiple Myeloma

Jiliang Xia, PhD, Jingyu Zhang, Bin Meng, Xuan Wu, Qian Lei, Yinghong Zhu, Yanjuan He, MD, Lugui Qiu, MD PhD, Wei Jia, PhD, Wen Zhou, PhD

Blood (2019) 134 (Supplement_1): 1791.

https://doi.org/10.1182/blood-2019-125452

Published: 2019

Journal Articles

The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy

Wei Liu, Rui Lv, Wenyang Huang, Hong Liu, Shuhui Deng, MD, Shuhua Yi, MD, Lulu Lv, Jianxiang Wang, MD, Lugui Qiu, MD PhD, Dehui Zou, MD

Blood (2019) 134 (Supplement_1): 2913.

https://doi.org/10.1182/blood-2019-126635

Published: 2019

Journal Articles

Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma

Xiaoyan Feng, Xin Wen, Ling Li, Xin Li, Sun Zhenchang, Lei Zhang, Lugui Qiu, MD PhD, Mingzhi Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 2851.

https://doi.org/10.1182/blood-2019-130091

Published: 2019

Journal Articles

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Gang An, MD, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3105.

https://doi.org/10.1182/blood-2019-130927

Published: 2019

Journal Articles

High Level of CCL3 in the Bone Marrow Microenvironment Promotes Anemia By Suppressing the Erythropoiesis Differentiation of Hematopoietic Stem Cells in Myeloma

Lanting Liu, MD, Shuhui Deng, MD, Cheng Tao, Lugui Qiu, MD PhD, Mu Hao

Blood (2019) 134 (Supplement_1): 1205.

https://doi.org/10.1182/blood-2019-123891

Published: 2019

Journal Articles

Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma

Wei Liu, Wenyang Huang, Rui Lv, Shuhui Deng, MD, Shuhua Yi, MD, Lugui Qiu, MD PhD, Dehui Zou, MD

Blood (2019) 134 (Supplement_1): 784.

https://doi.org/10.1182/blood-2019-127659

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Chenxing Du, An Gang, MD, Yan Xu, Xuehan Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Li Zengjun, Chengwen Li, Shuhua Yi, MD, Mu Hao, Dehui Zou, MD, Fenghuang Zhan, MD PhD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4343.

https://doi.org/10.1182/blood-2019-129739

Published: 2019

Journal Articles

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Yuting Yan, Yan Xu, Xuehan Mao, MD, Jiahui Liu, Huishou Fan, Qi Wang, Chenxing Du, Li Zengjun, Shuhua Yi, MD, Rui Lv, Shuhui Deng, MD, Weiwei Sui, Mu Hao, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Gang An, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4405.

https://doi.org/10.1182/blood-2019-124096

Published: 2019

Journal Articles

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Peter Hillmen, MD PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O'Brien, MD, Lugui Qiu, MD PhD, Tommi Salmi, MD, James Hilger, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 4307.

https://doi.org/10.1182/blood-2019-124213

Published: 2019

Journal Articles

Latent Membrane Protein 1 Contributes to Deficient Cellular Immunity in NKTCL Patients

Xiaoyan Feng, Yue Song, Zhaoming Li, MD PhD, Xudong Zhang, Lugui Qiu, MD PhD, Mingzhi Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 3969.

https://doi.org/10.1182/blood-2019-128622

Published: 2019

Journal Articles

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Shuhua Yi, MD, Wenjie Xiong, Yi Wang, Rui Lv, Li Zengjun, Wei Liu, Tingyu Wang, An Gang, MD, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4003.

https://doi.org/10.1182/blood-2019-130133

Published: 2019

Journal Articles

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

Lijie Xing, MD, Jiye Liu, PhD, Yuyin Li, PhD, Liang Lin, PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Tengteng Yu, MD PhD, Gang An, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4381.

https://doi.org/10.1182/blood-2019-130297

Published: 2019

Journal Articles

Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma

Xuehan Mao, MD, Yan Xu, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Zengjun Li, Lugui Qiu, MD PhD, Gang An

Blood (2019) 134 (Supplement_1): 4363.

https://doi.org/10.1182/blood-2019-125044

Published: 2019

Journal Articles

Excess Serine from the Microenvironment Caused the Impaired Megakaryopoiesis and Thrombocytopia in Multiple Myeloma

Chunmei Kuang, Meijuan Xia, Gang An, MD, Cuicui Liu, Dan Wu, Pei Su, Jingyu Zhang, Jiliang Xia, PhD, Jiaojiao Guo, Xuan Wu, Wei Jia, PhD, Lugui Qiu, MD PhD, Wen Zhou, PhD, Jiaxi Zhou

Blood (2019) 134 (Supplement_1): 4331.

https://doi.org/10.1182/blood-2019-125289

Published: 2019

Journal Articles

NEK2 Promotes Bortezomib Resistance through Enhancing Autophagy By Upregulation of Beclin1 in Multiple Myeloma Cells

Jiliang Xia, PhD, Yanjuan He, MD, Bin Meng, Jingyu Zhang, Xuan Wu, Xiangling Feng, PhD, Chunmei Kuang, Jiaojiao Guo, Yinghong Zhu, Qian Lei, Yongjun Guan, Yi Shen, MD PhD, Lugui Qiu, MD PhD, Wen Zhou, PhD

Blood (2019) 134 (Supplement_1): 4332.

https://doi.org/10.1182/blood-2019-126617

Published: 2019

Journal Articles

Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma

Chenxing Du, An Gang, MD, Yan Xu, Xuehan Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Li Zengjun, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 5491.

https://doi.org/10.1182/blood-2019-131730

Published: 2019

Journal Articles

High Frequency Mutations of MYD88 and KMT2D in Chinese Chronic Lymphocytic Leukemia

Shuhua Yi, MD, Yuting Yan, Meiling Jin, Dr., Wenjie Xiong, Zengjun Li, Ying Yu, Rui Cui, MD, Zhen Yu, MD, Yani Lin, Wang Jun, Tingyu Wang, Wei Liu, Kun Ru, MD, Lili Wang, MD PhD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 2761.

https://doi.org/10.1182/blood-2019-123194

Published: 2019

Journal Articles

Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways

Wenjie Xiong, Shuhua Yi, MD, Yuting Yan, Zengjun Li, Wei Liu, Rui Lv, Zhen Yu, MD, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 2566.

https://doi.org/10.1182/blood-2019-129860

Published: 2019

NARROW

Alterations of Gut Microbiome Accelerate Multiple Myeloma Progression By Increasing the Relative Abundances of Nitrogen Recycling Bacteria

High Glycine Promotes Proliferation and Progression Though Increase of Glutathione Synthesis in Multiple Myeloma

The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy

Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

High Level of CCL3 in the Bone Marrow Microenvironment Promotes Anemia By Suppressing the Erythropoiesis Differentiation of Hematopoietic Stem Cells in Myeloma

Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Latent Membrane Protein 1 Contributes to Deficient Cellular Immunity in NKTCL Patients

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma

Excess Serine from the Microenvironment Caused the Impaired Megakaryopoiesis and Thrombocytopia in Multiple Myeloma

NEK2 Promotes Bortezomib Resistance through Enhancing Autophagy By Upregulation of Beclin1 in Multiple Myeloma Cells

Immunophenotype Drift of Residual Plasma Cells Indicates Therapeutic Response and Prognosis in Multiple Myeloma

High Frequency Mutations of MYD88 and KMT2D in Chinese Chronic Lymphocytic Leukemia

Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only